Market snapshot
Starbucks is trading at $107.92, about 2.4% below its 52-week high, with a trailing price-to-earnings ratio of 62.0x. A fair-value model used here pegs intrinsic value at $92.70, implying the shares are approximately 14.1% overvalued at current prices. BMO has set a $120 price target and projects roughly $4 of EPS for fiscal 2028 - a view that is more bullish than consensus.
Key metrics
- Price: $107.92
- Market cap: $123.0B
- P/E LTM: 62.0x
- P/E Fwd: 41.2x
- Fair value: $92.70 (Fair Value Upside: -14.1%)
- Dividend yield: 2.3%
What BMO is arguing
BMO’s bullish case rests on three main elements: revised sales in North America that drive operating leverage, additional efficiency gains stacking on top of that leverage, and a fiscal 2028 EPS target of about $4.00 - a projection meaningfully above the consensus range of $3.66 to $3.75. The $120 price target, set on January 30, 2026, implies roughly 11.2% upside from current levels.
Those expectations hinge on a sustained earnings recovery. Reported EPS plunged from $3.58 in fiscal 2023 to $1.63 in fiscal 2025 - a 54% decline attributed in the reporting to heavier investment spending, elevated commodity costs, and international challenges. Consensus assumes a path back to $3.66 by fiscal 2028, which equates to about a 27% compound annual growth rate in EPS. BMO’s $4.00 estimate would require an additional roughly 9% on top of that trajectory.
Margins remain a constraint
Gross margin contracted from 27.4% to 23.0% over two years, while net margin dropped from 11.5% to 5.0% in the same span. For BMO’s operating-leverage story to fully materialize, those margins need to reverse. Management has announced a $2 billion cost-savings program that is still under way, and coffee commodity prices remain elevated. The implication noted here is straightforward: EPS growth absent margin recovery can amount to revenue growth that still burns cash.
How the market is already positioning
The stock has more than doubled from its 52-week low of $77.99, and at 62x trailing earnings for a company with a net margin that recently hit 5.0%, investors are effectively pricing in near-perfect execution of a turnaround. Additional comparative metrics include an EV/EBITDA of 24.8x and an analyst-implied target average near $112.10, which would translate to about 3.8% upside. Year-to-date return stands at +28.1%, reinforcing the view that much of the rally has already occurred.
Technical picture
Technically, the stock carries a Strong Buy signal across daily, weekly and monthly horizons. The daily relative strength index (RSI) sits at 59.2 - within healthy territory and not yet overbought - while the MACD is positive and expanding. That said, the shares are approaching their 52-week high of $110.51 and the weekly StochRSI is at 100, indicating maximum overbought conditions and a near-term pullback risk.
Earnings momentum
Recent quarterly results have supported the turnaround narrative. Two quarters in particular stood out:
- Q3 FY2026 (July 29): EPS of $0.85 versus an estimate of $0.66 - a 28.8% beat; stock moved about +2.7% on the print.
- Q2 FY2026 (April 28): EPS of $0.50 versus an estimate of $0.42 - a 19.1% beat; stock reacted with roughly +7.8%.
Following these results, 19 analysts revised earnings upward. The next quarterly report is scheduled for October 29, 2026, pre-market.
Investment verdict
The balance of evidence here supports a cautious stance. BMO’s $4.00 EPS thesis and $120 target are plausible if North America execution is strong, but they sit above consensus and require margin improvement that has not yet fully materialized. Valuation appears stretched at a 62x trailing P/E and 41x forward P/E, and the fair-value estimate used in this analysis indicates the shares are about 14.1% overvalued at current prices.
For prospective buyers, the risk/reward tends to favor waiting for a pullback toward the $95 to $100 range - closer to the stated fair value - rather than initiating new positions at the highs. For existing shareholders, recent earnings momentum gives reason to hold, but new capital deployed at these levels is effectively paying a premium for hoped-for operational progress rather than for confirmed, sustained margin recovery.